Introduction
Articular cartilage is an avascular, alymphatic, aneural, and hypocellular tissue. Such characteristics contribute to its low self-regenerative capacity. 1 Chondrocytes produce cartilage extracellular matrix (ECM) and, under physiological conditions, these cells efficiently contribute to tissue turnover. Nonetheless, under pathological conditions, such as large chondral defects, chondrocytes are unable to proliferate, migrate, and synthesize de novo cartilage ECM in order to promote tissue regeneration. 2 Current treatments are based on palliative strategies such as analgesics and nonsteroidal anti-inflammatory drugs administration; nonreparative such as debridement, chondral shaving, and knee joint lavage; and reparative such as microfracture, and subchondral drilling, which are based on stimulation of proliferation and differentiation of subchondral bone marrow progenitor cells resulting in fibrous tissue formation. 3 Cell-based therapies emerged as a promising clinical intervention in cartilage defect repair. Autologous chondrocyte implantation (ACI) is one such approach whereby autologous chondrocytes are isolated from a healthy nonweight bearing region of the joint, expanded in vitro, and subsequently implanted into the lesion. 4, 5 Second-and third-generation ACI approaches, which rely on the use of collagen membranes and porous scaffolds, respectively, have demonstrated more advanced regenerative potential. 6 However, the drawbacks associated with the use of autologous chondrocytes still prevail, including donor site morbidity and limited tissue source. Moreover, fibrous tissue formation after cell implantation is associated with a major drawback, chondrocyte dedifferentiation during in vitro expansion. 7, 8 Although the use of recombinant factors such as TGF-β1, FGF-2, PDGF-BB, and IGF-1 can effectively promote chondrocyte redifferentiation in vitro, 9-11 the production of such therapeutics represents a high cost procedure. These and other factors such as TGF-β2, 12 HGF, 13 and BMP-2, 14 which have also been shown to stimulate chondrogenesis in vitro, are present in platelet alpha granules and are released upon platelet activation. 15 These observations indicate that platelet-rich plasma releasate (PRPr) might be an interesting source of chondrogenic factors.
Platelets can be easily and cost-effectively separated from other blood components, concentrated in plasma to form platelet-rich plasma (PRP), and when activated with exogenous thrombin or calcium can trigger endogenous thrombin formation and importantly the release of high concentrations of different cytokines and growth factors. 16 It has been recently reviewed that although preclinical and clinical reports generally show promising histological and clinical results when PRP is used in vivo, there is still inconclusive scientific evidence to support its use for the repair of cartilage defects. [17] [18] [19] Besides articular chondrocytes, many cell types have been identified as promising for future cell therapy protocols to treat cartilage defects. 20, 21 Some progenitors are found in an undifferentiated state, as mesenchymal stromal cells (MSCs), and others are already committed to the chondrogenic lineage, as human nasoseptal chondrogenic cells (NCCs). MSCs are characterized mostly by their multipotency and ability to originate colonies of fibroblast-like cells in vitro. 22, 23 These cells can be isolated from a range of different tissue types such as bone marrow, adipose tissue, and synovia. 24 Although MSCs could be used therapeutically for cartilage repair, 3 the addition of growth factors is traditionally required to promote their differentiation toward the chondrogenic lineage in vitro, in particular, factors from the TGF-β superfamily. 25 Human NCCs, on the other hand, residing on the surface of the nasoseptal hyaline cartilage, can be easily harvested and cultured, and have been demonstrated to have an intrinsic chondrogenic commitment. In the absence of growth factors, NCCs up to the third passage are able to synthesize a hyaline-like cartilage in a pellet culture system. 26 The chondrogenic capacity of progenitor cells from the nasal septum is also being investigated by other groups. [27] [28] [29] Using two different cell culture models, NCCs and MSCs, the aim of this study was to investigate the effect of PRPr on cell proliferation and commitment (or loss of it) toward the chondrogenic lineage in vitro.
Materials and methods

PRP preparation
Two methods for PRPr preparation were used. The first protocol was based on using platelet concentrate bags, which would not be used in clinics, following approval from the Research Ethics Committee of the Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (201042).
Platelet concentrate (n = 7) was transferred to 50 mL Falcon tubes (Corning Incorporated, Corning, NY, USA). Platelet counting was performed by the Brilliant Blue Cresyl (Sigma Chemical Co., St Louis, MO, USA) staining and observation under hemocytometer. For inducing platelet activation, 1 M CaCl 2 solution was added to tubes, in a proportion of 1:50, reaching a final concentration of 20 mM CaCl 2 . Tubes were maintained at 37°C for 1 h, after that a clot was formed. Tubes were then incubated overnight at 4°C for clot retraction. Finally, tubes were centrifuged at 3000 r/min for 5 min (Centrifuge 5810 R; Eppendorf). The final supernatant (PRPr) was frozen at −20°C for future in vitro analysis.
The second protocol was based on immediate use of blood collection, following consent and under the Royal College of Surgeons in Ireland (RCSI) Ethics Committee approval (REC676), as previously described, with minor modifications. 30 Briefly, 54 mL peripheral blood from six donors (n = 6) was collected into 60-mL syringe filled with 6 mL of 3.2% sodium citrate solution (Sigma). Blood was transferred to 50-mL tube (Corning) and centrifuged at 300g for 5 min. The buffy coat and the red blood cell layer remained intact, while the upper fraction was transferred to new tubes, which was further centrifuged at 700g for 17 min. After second centrifugation step, platelets pellet was resuspended with the supernatant (platelet-poor plasma), forming the inactivated PRP. Platelets were counted using a hematology analyzer (Sysmex, Kobe, Japan). The platelet activation was achieved as previously described for protocol 1.
Scaffold fabrication
Collagen-hyaluronic acid (CHyA) scaffolds were fabricated as previously described. 31 Briefly, collagen type I derived from bovine Achilles tendon (Collagen Matrix, Oakland, NJ, USA) and hyaluronic acid (HyA) sodium salt derived from streptococcus equi (Sigma-Aldrich, Arklow, Ireland) were blended with a 0.5 M acetic acid (Sigma) solution to give suspensions with final concentrations of 0.5% (w/v) collagen and 0.05% (w/v) HyA. Subsequently, the suspensions were freeze-dried (Virtis Genesis 25EL; Biopharma, Winchester, UK) to a final freezing temperature of −10°C with an additional annealing step prior to drying. The resultant scaffolds were then crosslinked using dehydrothermal treatment (DHT) under vacuum of 50 mTorr and a temperature of 105°C in a vacuum oven (VacuCell; MMM, Germany) for a duration of 24 h.
NCC isolation and culture
Human NCCs were isolated and cultured as previously described. 26 Briefly, cartilage fragments from nasoseptal were obtained from three donors (n = 3) that underwent aesthetic surgery procedures, with informed consent and with the approval of the Research Ethics Committee of the Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Brazil (766/09). Fragments were rapidly incubated with collagenase IA (Sigma). Cells were harvested by centrifugation and cultured in tissue culture flasks with Iscove's Modified Dulbecco's Medium (IMDM; Sigma Chemical Co.) containing 10% fetal bovine serum (FBS; LGC), 100 U/mL penicillin, and 100 µg/mL streptomycin. Cultures were maintained at 37°C in a humid atmosphere with 5% CO 2 , and the medium was changed twice a week until cell monolayer reached 80%-90% confluence. By this level, cells were harvested with 0.78 mM ethylenediaminetetraacetic acid (EDTA; Gibco BRL, Rockville, MD, USA) and 0.125% trypsin (Gibco) and re-seeded at a density of 10 4 cells/cm 2 . Dissociation with trypsin followed by re-seeding for cell expansion was denominated "passage." Time elapsed on each passage was about 1 week. Freshly isolated cells, that is, isolated from fragments but not underwent trypsin harvesting yet, were considered to be on passage 0. Until passage 1, all cells were cultured with 10% FBS. For threedimensional (3D) culture, NCCs in third and fifth passages were transferred to pellet culture system (n = 3, for each condition). 32 For third passage pellets, cells were cultured in passage 2 in 10% FBS (control condition), 2.5% PRPr or 10% PRPr. For fifth passage pellets, cells were cultured in passages 2, 3, and 4 in 10% FBS (control condition), 2.5% PRPr, or 10% PRPr. In another experiment, cells were cultured in 10% FBS until passage 3 and on passage 4 the medium was changed to 2.5% PRPr or 10% PRPr. The PRPr used in these experiments was pooled from four different donors. For pellet assembly, cells were harvested and centrifuged at 300g for 10 min into 15-mL tubes (Corning) at a concentration of 2 × 10 5 cells/tube. Media was replaced twice a week, while the pellets remained intact. Chondrogenic control media was composed of IMDM (Gibco) supplemented with 1 µM insulin (Sigma), 8 × 10 −8 M transferrin (Sigma), 2 × 10 −8 M bovine serum albumin (Sigma), and 2.5 × 10 −4 M ascorbic acid (Sigma). For the chondrogenic inductor medium, 10 ng/mL TGF-β2 (R&D Systems, MN) was added to the chondrogenic control medium. In some experiments, IMDM supplemented with 10% FBS (control condition), 1% PRPr, 2.5% PRPr, or 10% PRPr were directly used to culture pellets. After 21 and 35 days, cultures were fixed in 4% paraformaldehyde and embedded in paraffin for histological analysis. The culture conditions for NCCs are summarized in a table of culture conditions (Table 1) .
MSC isolation and culture
Human MSCs (hMSCs) were commercially acquired (PT-2501; Lonza, Switzerland). Cells were expanded in culture using hMSC growth medium consisting of low-glucose Dulbecco's modified Eagle's medium (DMEM; SigmaAldrich) supplemented with 1% penicillin/streptomycin (Sigma-Aldrich) and 10% FBS and maintained in a tissue culture incubator at 37°C and 5% CO 2 . Cells were detached from culture flasks using trypsin EDTA (Sigma-Aldrich). Subsequently, cells were counted and resuspended at a cell density of 10 × 10 6 cells/mL of medium. For 3D culture, 9.5-mm diameter, 4-mm height scaffolds were prehydrated in phosphate buffered saline (PBS) for 15 min at room temperature. The excess PBS was removed from the scaffolds, which were then placed onto 24-well suspension plates (Sarstedt, Drinagh, Ireland). A total of 0.5 × 10 6 cells were seeded onto each scaffold (0.25 × 10 6 cells on each side of the scaffold). The scaffolds were subsequently incubated for 15 min before addition of medium. The medium was changed every 3 days from the scaffolds, and the study was carried out for 14 days. The medium was supplemented with either PRPr alone (2.5% or 10%) or a combination of PRPr (2.5% or 10%) and chondrogenic factors or a combination of 10% FBS and chondrogenic factors (control condition). In one condition, cells were previously expanded on 2.5% PRPr supplemented hMSC growth medium in substitution to 10% FBS prior to seeding onto the scaffolds. The chondrogenic factors were 20 ng/mL human TGF-β3 (Prospec, Rehovot, Israel), 50 µg/mL ascorbic acid (SigmaAldrich), 40 µg/mL proline (Sigma-Aldrich), 100 nM dexamethasone (Sigma-Aldrich), 1× ITS (Insulin, Transferrin, Selenium) (BD Biosciences, Oxford, UK), and 0.11 mg/mL sodium pyruvate (Sigma-Aldrich). The culture medium supplemented with these chondrogenic factors was termed as chondrogenic medium (CM). The PRPr used in these experiments was pooled from four different donors. After 14 days, samples were separated for gene expression analysis (n = 3, for each condition), sulfated glycosaminoglycan (sGAG) quantification (n = 3, for each condition), and compressive modulus evaluation (n = 3, for each condition). The culture conditions for MSCs are summarized in a table of culture conditions (Table 1) .
Cell proliferation assay
Cells were seeded in 96-well plates in quadruplicates at 1.2 × 10 4 cells/cm 2 . Cells were cultured for up to 7 days in IMDM (Gibco) supplemented with 10% FBS (control condition) or PRPr in different concentrations (from 1% to 10%). Medium was not changed until the end of treatment. For this experiment, three PRP samples were used as well as a mix of those samples in equal parts for each cell type. Neutral red uptake assay was performed to evaluate cells viability, due to its higher economic advantages and sensibility than other cytotoxicity tests. 33 Briefly, 0.005% neutral red (Sigma) solution was incubated for 3 h. A solution containing 50% ethanol, 1% acetic acid, and 49% water was added to elute the red staining, and absorbance was measured at 490 nm (Spectramax M5; Molecular Devices, Sunnyvale, CA, USA). Since the number of cells seeded was similar in every condition, the increase in the number of viable cells over time indicates cell proliferation.
Histology
Samples were fixed in 10% formalin for 1 h and using a Histokinette tissue processor (Leica TP1050), were dehydrated and paraffin wax embedded. Blocks of wax embedded samples were serially sectioned using a microtoming machine (Leica RM2255) which sliced the samples at 5-µm-thick sections. The sections were successively mounted on polylysine-coated glass slides (FisherScientific, Ireland). The slides were deparaffinized and hydrated before they were stained with alcian blue 1% at pH 1.0 (w/v, pH 1.0) (Sigma), to demonstrate sGAG deposition. Then, slides were counterstained with neutral red 0.5% (w/v) (Sigma). The sections were subsequently dehydrated and mounted with cover slides using distyreneplasticizer-xylene (DPX). Images were obtained with a microscope (Leica DMI 6000 B) equipped with a digital camera (Leica DFC 500). Alcian blue pH 1.0 staining is routinely used on in vitro chondrogenic induction protocols. [34] [35] [36] [37] [38] [39] At low pH, all carboxylic and phosphoric acid groups are neutralized, and at a high ionic strength, this tetravalent cation strongly binds to some negatively charged polymers, as glycosaminoglycans (GAGs), but not others, as nucleic acids. 40 The analyses of stained sections focused on the determination of the presence of hyaline cartilage characteristics, as an ECM rich in sGAG, where a more intense blue-colored ECM is an indicator of higher sGAG deposition, cells with a round chondrocyte morphology, and an outer fibroblastic perichondrium-like zone.
Pellet area measurement
After samples were fixed, but before dehydration for paraffin embedment, images were obtained with a microscope (Leica DMI 6000 B) equipped with a digital camera (Leica DFC 500). Low magnification was used in order for the entire sample to be captured. The measurement of the pellet area in those images was then performed using the Fiji Is Just ImageJ 1.49a software. 41 
Quantitative polymerase chain reaction
For gene expression analysis, total RNA was isolated using an RNeasy kit (Qiagen, Crawley, UK) as previously described (Duffy et al., 2011). A total of 200 ng of total RNA was reverse transcribed to complementary DNA (cDNA) using a QuantiTect reverse transcription kit (Qiagen) on an authorized thermal cycler (Mastercycler Personal; Eppendorf, Stevenage, UK). Real-time polymerase chain reactions (PCRs) were run on 7500 real-time PCR System (Applied Biosystems, Paisley, UK) using a QuantiTect SYBR Green PCR Kit (Qiagen). The relative expression of messenger RNA (mRNA) was calculated by delta-delta Ct (ΔΔCt) method, where the fold increase of gene expression was 2 −(ΔΔCt) . 42 Target mRNA analyzed were SOX9, COL2A1, ACAN, and COL10A1, with GAPDH used as a housekeeping gene.
sGAG quantification
For sGAG quantification, scaffolds were digested in papain enzyme solution containing 0. 
Mechanical testing: compressive modulus analysis
For compressive modulus evaluation, unconfined compressive testing was carried out on seeded scaffold samples incubated in PBS using a mechanical testing machine (Zwick-Roell, Rehovot and Ulm, Germany). Briefly, the mechanical testing machine (Z050; Zwick-Roell, Germany) was fitted with a 5-N load cell and tests were conducted at a strain rate of 10% per minute with each sample being tested three times. Stress was calculated from scaffold surface area and applied force, while strain was calculated from displacement of the scaffolds in relation to the original thickness. The compressive modulus was defined based on the slope of a linear fit to the stressstrain curve over 2%-5% strain.
Statistical analysis
Results are expressed as mean ± standard deviation for at least three replicates. One-way nonparametric analysis of variance followed by the Tukey post-hoc test (to compare all pairs in group) was assessed to verify statistical significance; p < 0.05 was considered statistically significant. Statistical analysis was performed using Prism 5.00 software (GraphPad Software Inc., San Diego, CA, USA).
Results
PRPr formulation
Platelet concentration may differ according to the method used to obtain PRP. Herein, we have tested two different centrifugation methods to concentrate platelets and no statistical difference was observed between them. Out of 13 patients, platelet numbers varied from 0.92 to 3.76 × 10 6 µL −1 . These concentrations were further considered to prepare PRPr.
PRPr effect on NCCs
NCC proliferation. To evaluate PRPr activity on cell expansion in vitro, NCCs were cultured in 1%, 2.5%, 5%, and 10% of PRPr supplemented culture medium (Figure 1(a) ). Cells cultured in 2.5% of PRPr presented a similar proliferation rate compared to 10% FBS and maintained similar phenotype (Figure 1(b) and (c) ). However, the proliferation rate increased when cells were cultured in 5% and 10% of PRPr, and NCCs changed to small polygonal-shaped cells when cultured in 10% PRPr (Figure 1(d) ). After these observations, further experiments were achieved only with 2.5% and 10% PRPr. All experiments were achieved using 10% FBS as reference.
PRPr onto NCC pellets. To evaluate PRPr capacity to induce chondrogenic differentiation, third passage NCCs were cultured in 3D pellet system for 21 days in different concentrations of PRPr, as described. PRPr direct administration onto the pellet culture failed to promote full chondrogenic differentiation of NCCs in vitro ( Figure  1 (e)-(g)). However, pellets cultured in 10% PRPr ( Figure  1(g) ) presented more intense staining for synthesized ECM, as well as some round-shaped chondrocyte-like cells. Of note, all PRPr-treated pellets presented an outer layer of cells circulating the pellets, in a perichondriumlike structure.
PRPr pre-treatment on low-passage NCCs. Hereafter, NCCs were cultured in two-dimensions (2D) in 2.5% PRPr, 10% PRPr, and 10% FBS in passage 2 and then transferred to 3D pellet culture in passage 3 with or without TGF-β, to evaluate cartilage-like formation ( Figure 2 ). Similar cartilage-like pellets were formed in all three conditions. However, it can be noticed that, after 21 days of culture, 2.5% PRPr treatment resulted in pellets that best resemble a hyaline cartilage-like structure, with intense ECM staining and more cells with chondrocyte-like morphology. Although no statistical significance was observed, PRPr-treated pellets, in special 10% PRPr, were also larger than 10% FBS-treated pellets (Figure 4 
(a)). Only after 35 days, 10% FBS treatment resulted in pellets with intense ECM staining, high number of cells with chondrocyte morphology and as large as PRPr-treated ones (Figures 2 and 4(b)).
PRPr pre-treatment on high-passage NCCs. As observed (Figure 2 ), NCCs can originate a cartilage-like pellet up to the third passage when pre-treated with FBS or PRPr. However, higher passage expansion with FBS is associated with chondrocyte dedifferentiation and loss of chondrogenic capacity. 7, 8 To test whether a similar process would happen with NCCs and how PRPr could affect it, NCCs were expanded in 2D cultures from passage 2 to passage 4 in the presence of 2.5% and 10% PRPr and then changed to 3D pellet cultures on the fifth passage. Expansion in 10% FBS was used as control ( Figure 3 ). Expansion in 10% FBS clearly hampered NCCs cartilagelike pellet formation. A fibrous inner spot with poor cartilage-like histological characteristics was observed. Only in a few spots of the pellet, cells from the periphery demonstrated mild chondrogenic differentiation. Conversely, PRPr pre-treatment resulted in pellets with intense sGAG production and mostly cells with typical chondrocyte morphology. Moreover, both 2.5% and 10% PRPr pretreated pellets were significantly larger than 10% FBS pre-treated pellets, all cultured under TGF-β induction, after 21 days of culture. No difference was observed between the two concentrations of PRPr whatsoever (Figure 4(c) ). After 35 days of culture under TGF-β induction, 2.5% PRPr pre-treated pellets were again larger than the other groups, although with no statistical significance (Figure 4(d) ). PRPr and NCC chondrogenic recommitment. The data presented above indicate that PRPr could prevent NCCs loss of chondrogenic potential after in vitro expansion, at least up to the fifth passage, even at low concentrations. To test whether the releasate would stimulate phenotype "recovery" after NCCs expansion, fourth-passage NCCs were cultured in the presence of PRPr only one passage prior to 3D pellet culture. Our results showed that cells recommitted and differentiated toward the chondrogenic lineage when pre-treated with PRPr ( Figure 3 ). Pellets cultured in these conditions showed evidence of chondrogenesis with more intensively stained and a large area of synthesized sGAG-rich matrix, and more clear round chondrocyte-like cells, than those that were cultured in 10% FBS until passage 4 ( Figure 3 ). Although those remarkable chondrogenic histological characteristics could be found both in 2.5% PRPr and 10% PRPr pre-treated on passage 4 pellets, the 2.5% PRPr pre-treated ones were significantly larger than 10% FBS pre-treated pellets from passage 2 to passage 4 under TGF-β induction and after 21 days of culture (Figure 4(c) ).
PRPr effect on MSCs
PRPr effect on MSC proliferation and chondrogenic gene expression. As compared to NCCs, 2.5% PRPr also presented the most similar effects on MSCs proliferation compared to 10% FBS ( Figure 5(a) ). To verify their chondrogenic differentiation, passage 7 MSCs were seeded on CHyA scaffolds for 14 days in the presence of 2.5% and 10% PRPr alone or in CM supplemented with 2.5% PRPr and 10% PRPr. CM supplemented with 10% FBS was used as reference. FBS group was divided into two subgroups, as MSCs were pre-treated on passage 6 with 10% FBS or 2.5% PRPr. A higher SOX9 expression was observed on PRPr-based conditions ( Figure 5(b) ), as well as COL2A1 ( Figure 5(c) ), with the exception of CM supplemented with 10% PRPr. Low concentrations of PRPr led to the highest ACAN expression ( Figure 5(d) ). CM supplemented with 2.5% PRPr presented COL10A1 expression statistically similar to the control group, which was the CM supplemented with 10% FBS, with cells expanded in 10% FBS ( Figure 5(e) ).
PRPr effect on MSC sGAG production and CHyA seeded biomechanical properties. To verify whether higher chondrogenic gene expression on PRPr groups resulted in higher biochemical and biomechanical improvement, sGAG production and compressive modulus evaluation were performed. Biochemical analyses evidenced that higher sGAG production was observed in the CM supplemented with 2.5% PRPr. On the other hand, other conditions showed lower amount of sGAG production than the control group (Figure 6(a) ). The groups in which PRPr replaced FBS in the CM presented higher mechanical properties than those maintained in FBS. In contrast, PRPr alone, that is, without the addition of CM, was not enough to induce higher levels of compressive modulus, with values remaining even lower than in CM groups supplemented with 10% FBS (Figure 6(b) ).
Discussion
In this study, using two different cell culture models, we observed that PRPr efficiently modulated cells proliferation, chondrogenic commitment, and differentiation, in a concentration-dependent manner. PRP concentration apparently has a great impact on clinical outcomes. For bone regeneration, platelet concentration in PRP has an optimal limited concentration range, approximately 10 6 µL −1 (five times higher than the 200 × 10 3 µL −1 average platelet concentration in peripheral blood). Lower concentrations present suboptimal effects; on the contrary, higher platelet concentration seems to inhibit bone growth. 43 When we cultured cells in 2.5% PRPr, the releasate induced cell proliferation similarly to 10% FBS, both NCCs and MSCs. Other studies pointed PRP concentration around 1% in cells culture medium to be similar to the control group regarding cell proliferation. 44, 45 On the other hand, human platelet lysate used to expand adipose-derived mesenchymal progenitor cells at the concentration of 2.5% has been previously shown to maintain cells phenotype and ability to differentiate toward adipogenic lineage. 46 Our data also showed that no significant increase in cell proliferation Figure 3 . Effect of PRP pre-treatment on passage 5 pellet culture system. Pellets of cells which were pre-treated in 2D from passage 2 to passage 4 in the presence of 10% FBS, 2.5% PRPr, and 10% PRPr, or until passage 3 in 10% FBS and only in passage 4 in the presence of 2.5% PRPr and 10% PRPr, for 21 or 35 days. Pellets were cultured in serum-free medium with (w/) or without (w/o) TGF-β. Sulfated GAGs evidenced by alcian blue pH 1.0 staining (blue) and cells nuclei by neutral red (red). Inner fibrous layers of 10% FBS pre-treated pellets are highlighted in ellipses. Scale bars: 100 µm.
was induced when PRPr concentration was changed to 5% and 10%, probably due to the reach of an optimal induction of proliferation already at the concentration of 5%. This phenomenon has been reported previously by another group using articular chondrocytes. 47 For meniscus cell culture, no difference in proliferation results has been reported when increasing from 10% to 20% PRP. 48 For fibroblasts, the plasma rich in growth factors (PRGF) had similar effects on tendon and skin-derived, while a dose-dependent effect was seen on synovium-derived, according to platelet concentration. 49 NCCs changed to possess a small polygonal-shape when cultured in higher concentrations of PRPr, compared to the fibroblast-like morphology in lower concentrations of PRPr and the FBS. This change in cell morphology may be correlated to their proliferation rate, where 10% FBS and 2.5% PRPr are similar and 10% PRPr is higher than both. Probably, the lower proliferation rate allows cells to elongate and acquire a fusiform fibroblast-like morphology in culture, which does not occur when cells proliferate more rapidly. To assess the effects of PRPr on cells chondrogenic commitment, a pellet culture system was chosen for NCCs to readily verify through histological analysis this already committed cell population chondrogenic capacity. On the other hand, a scaffold system was chosen for MSCs, as it represents a model for future tissue engineering therapy approach with undifferentiated cells extensively used for this purpose. In this case, gene expression and biochemical and biomechanical analyses were done to evaluate chondrogenic differentiation. When PRPr or FBS were directly incorporated within the NCCs pellets cultures, it was not possible to achieve a chondrogenic differentiation as expected. Similar to our findings, synovium-derived MSC pellets cultured directly in the presence of PRP did not present chondrogenic differentiation, which was only successfully achieved in the presence of a CM supplemented with BMP-2 and TGF-β1. 50 In fact, pellet culture system is usually performed under serum-free conditions. 32, 51 Because of this, instead of adding PRPr directly to pellets, the cells were expanded in the presence of PRPr and subsequently cultured in 3D pellets at the following passage. This approach has previously been utilized for canine chondrocytes, by priming cells with TGF-β1, basic fibroblast growth factor (bFGF), and PDGF-BB, which are also present in PRP. 30 In that study, although cell priming during monolayer expansion led to a dedifferentiated phenotype, later pellet culture demonstrated their higher chondrogenic feature compared to control group, where those growth factors were not present. 52 At low passage, 2.5% PRPr was enough to further induce NCCs chondrogenic differentiation after a shorter period than cells expanded in 10% FBS. This could be interpreted as the ability of cells to more promptly respond to chondrogenic induction when treated with a low concentration of PRPr compared to 10% FBS. At high passage, cells which have been cultured on PRPr showed pellets with a more similar morphology to hyaline cartilage than those from cells previously cultured on 10% FBS. In vitro culture can alter cell physiology and lead to a loss of chondrogenic capacity, 11 and PRPr was able to prevent and reverse it. Taken together with the pellet area measurement results, it is possible to conclude that the use of PRPr at the concentration of 2.5% was enough to maintain NCCs chondrogenic commitment and to induce its recommitment when lost after FBS expansion. Although other in vitro studies point PRP as a dedifferentiation/ fibrogenic inducer, 44, 53 our results are in accordance with studies that demonstrate PRP in vitro chondrogenic induction on chondrocytes. 47, 54 PRPr supported SOX9, COL2A1, and ACAN gene expression, markers of chondrogenic lineage, and COL10A1 expression, marker of chondrocytes hypertrophy on MSCs seeded on CHyA scaffolds. However, the use of CM supplemented with 2.5% PRPr showed the most remarkable characteristics regarding chondrogenic induction, as well as basal levels of COL10A1 expression. Interestingly, CM supplemented with 10% PRPr did not show increase in COL2A1, as well as presented high levels of COL10A1, which could be an indicator of hypertrophy. However, further evaluation to support the hypothesis of a higher amount of PRPr being related to MSCs hypertrophy is still needed. Although PRPr alone was sufficient to increase some chondrogenic genes, probably due to post-transcription factors, it was not able to induce greater sGAG production nor biomechanical properties, only achieved when CM was also present. The highest sGAG content was observed in the samples cultured with CM supplemented with 2.5% PRPr, while in CM supplemented with 10% PRPr it was lower than the control group. The highest compressive modulus was achieved in CM supplemented with PRPr groups, followed by CM supplemented with FBS groups and finally by PRPr alone groups. Interestingly, the compressive modulus did not present significant difference between 2.5% and 10% PRPr alone or in the presence of CM. In addition, although CM supplemented with 10% FBS had smaller effect on chondrogenic gene expression, the compressive modulus of these scaffolds was higher than of the ones treated with PRPr alone. These could be explained by the fact that the increase in compressive modulus is correlated to various factors. For example, sGAG content has a modest correlation to compressive modulus on tissue-engineered constructs. Other ECM components and the remodeling of the construct throughout culture also affect its mechanical properties. 55 The pre-expansion of MSCs on the passage prior to scaffold culture, in a similar way that it was investigated for NCCs, was not possible to induce a higher chondrogenic capacity than those pre-treated with 10% FBS.
Taken together, these results point that the presence of CM for MSC chondrogenesis in this model is highly important. Moreover, the substitution of the traditionally used 10% FBS supplementation in the CM by 2.5% PRPr showed to be an interesting strategy, as evidenced by gene expression, sGAG synthesis, and compressive modulus measurement, while by 10% PRPr could represent hypertrophy. A low concentration of PRPr enhanced the capacity of MSCs to differentiate to the chondrogenic lineage compared to 10% FBS, and although in a different model, in a similar way of the NCCs findings. Nevertheless, as in an undifferentiated state, a higher PRPr concentration could induce MSCs to a different phenotype. It has been shown that when PRP clot is added directly to culture, it presented an inhibition toward chondrogenesis both for chondrocytes and MSCs. 56 Probably, the differences in PRP concentration in medium could explain this opposing result compared to our study. On the other hand, it has been recently reviewed that PRP showed to enhance, or at least did not hinder, MSCs chondrogenic phenotype in vitro. 57 Also, the role of PRP as a valid augmentation for cartilage scaffolds has been investigated in a number of preclinical studies with the majority confirming promising results for scaffolds combined with PRP. 17 Finally, the different effects of low and high concentrations of PRPr on cells chondrogenesis can also be discussed under the light of cell proliferation. It has been shown that between day 0 and day 7 of pellet culture system, the number of MSCs is increased in 30%, thus indicating cell proliferation. From day 7, the number of cells decreases, and collagens, proteoglycans, and other matrix components' gene expression is generally upregulated. 58 Proliferation is indeed a requirement for in vitro chondrogenesis of MSCs. Treatment with mitomycin C, which blocks proliferation, hampered MSC chondrogenic differentiation. On the other hand, little proliferation is observed after 21 days in pellet culture system in areas with strong matrix deposition. 34 Those in vitro studies seem to mimic embryonic chondrogenesis, where cells initially undergo extensive proliferation, which eventually stops prior to matrix deposition and cartilaginous nodules formation. 59, 60 Thus, the results in this work showing greater enhancement of chondrogenic phenotype under 2.5% PRPr treatment rather than 10% PRPr may be correlated to the more intensive effect on cell proliferation by 10% PRPr than 2.5% PRPr.
Conclusion
In the work presented in this article, it was possible to produce a PRPr capable of eliciting an enhanced chondrogenic effect in vitro, which when used as a substitute to FBS prevented NCCs dedifferentiation as well as promoted their redifferentiation toward the chondrogenic lineage. In the case of MSCs, PRPr induced the expression of chondrogenic markers, production of sGAG, and increase in biomechanical properties in a scaffold culture system. Collectively, we can conclude that PRPr can be used as a substitute for FBS for in vitro 2D expansion of chondrogenic cells, with special regard to its concentration, cell type, and passage. Further work is required to confirm whether cellular expansion with PRPr will enhance cartilage repair in vivo.
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